ChemoCentryx Inc.

ChemoCentryx Inc is a biopharmaceutical company. It works to discover, develop, and commercialise orally administered medications to treat cancer, autoimmune diseases, and inflammatory disorders. The company's lead drug candidate, Avacopan, is in phase III development. Founded in 1996 and operating within the US, ChemoCentryx Inc has its headquarters in Mountain View, California. Available under the CCXI ticker, the company is listed on the NASDAQ GS stock exchange. As of December 2020, the CCXI share price had ranged from a 52-week low of $30.72 in March 2020 before rising to a 52-week high of $65.43 in May 2020. This stock provided a 93.96% one-year return as of December 2020. On December 4, 2020, this stock was trading at $57.47. ChemoCentryx Inc's research focuses on the role that discrete chemokine and chemoattractant receptors play in how specific diseases progress. In addition to Avacopan, the company has a number of other drugs in the pipeline, including CCX872 for the treatment of stage 3 and 4 pancreatic cancer and AURORA for the treatment of moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. The company is also working towards treatments to slow and/or halt the progression of diabetic nephropathy. Add CCXI stock to your eToro watchlist to keep up to date with the latest news and information about this instrument.